Shigefuku, R.; Iwasa, M.; Tanaka, H.; Tsukimoto, M.; Tamai, Y.; Fujiwara, N.; Yoshikawa, K.; Tameda, M.; Ogura, S.; Nakagawa, H.
Prognostic Significance of Psoas Muscle Index in Unresectable Hepatocellular Carcinoma: Comparative Analysis of Lenvatinib and Atezolizumab Plus Bevacizumab. J. Clin. Med. 2024, 13, 5925.
https://doi.org/10.3390/jcm13195925
AMA Style
Shigefuku R, Iwasa M, Tanaka H, Tsukimoto M, Tamai Y, Fujiwara N, Yoshikawa K, Tameda M, Ogura S, Nakagawa H.
Prognostic Significance of Psoas Muscle Index in Unresectable Hepatocellular Carcinoma: Comparative Analysis of Lenvatinib and Atezolizumab Plus Bevacizumab. Journal of Clinical Medicine. 2024; 13(19):5925.
https://doi.org/10.3390/jcm13195925
Chicago/Turabian Style
Shigefuku, Ryuta, Motoh Iwasa, Hideaki Tanaka, Mone Tsukimoto, Yasuyuki Tamai, Naoto Fujiwara, Kyoko Yoshikawa, Masahiko Tameda, Suguru Ogura, and Hayato Nakagawa.
2024. "Prognostic Significance of Psoas Muscle Index in Unresectable Hepatocellular Carcinoma: Comparative Analysis of Lenvatinib and Atezolizumab Plus Bevacizumab" Journal of Clinical Medicine 13, no. 19: 5925.
https://doi.org/10.3390/jcm13195925
APA Style
Shigefuku, R., Iwasa, M., Tanaka, H., Tsukimoto, M., Tamai, Y., Fujiwara, N., Yoshikawa, K., Tameda, M., Ogura, S., & Nakagawa, H.
(2024). Prognostic Significance of Psoas Muscle Index in Unresectable Hepatocellular Carcinoma: Comparative Analysis of Lenvatinib and Atezolizumab Plus Bevacizumab. Journal of Clinical Medicine, 13(19), 5925.
https://doi.org/10.3390/jcm13195925
